TickerTalks
Browse all tickers →
TickerTalks›$KALA
KAKALA

KALA BIO, Inc.

$KALA·$11M·Biotechnology·Healthcare
$0.54+3.5%YTD-98.1%1Y-99.9%
Price updated 3m ago·X counts updated 3d ago
KAKALA
$KALAKALA BIO, Inc.
$0.54+3.55%49 posts1×
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $KALA on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

49X posts · last 7 days
Sep 1Sep 14
Chatter Meter
1×
QuietNormal · 1×Loud

How loud $KALA's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $KALA — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Broken storySelling offAI verdict · as of 2026-09-17

Falling on heavy selling — points lower unless it turns around.

KALA BIO down 98% YTD with a Nasdaq bid-price deficiency — the ophthalmology micro-cap is essentially priced for zero.

KALA BIO is an ophthalmology-focused biotech developing nanoparticle-based drug therapies — a small business whose stock has essentially collapsed post-listing. Shares are down 98% YTD and 99.9% year-on-year, priced at $0.52 on a $0M cap — value-decimation territory.

  • The financial baseline is pre-commercial and terminally small: Q1, Q2 revenue were $0 with mostly quarterly EPS losses averaging pennies-per-share off tiny bases — the last three quarterly EPS surprises have been erratic (-255%, +98%, +100%). This is a story-stock trading essentially on distress dynamics.
  • The listing-compliance signal is bad: KALA received a Nasdaq deficiency letter on Aug 27 for closing below the $1 minimum bid price for 30 consecutive business days — the specific listing-compliance clock that gates institutional flow. The Sept 10 Virotek partnership for ophthalmic genetic-testing distribution on a 50/50 profit share adds tiny optionality.

Nov 10 Q3 earnings and any Nasdaq compliance resolution are the switches — a reverse stock split or a fresh capital-raise is what could keep the stock listed, while continued sub-$1 trading with no compliance action confirms the terminal drift.

What to watch: Nov 10 Q3 earnings, any reverse stock split or capital-raise action, and Nasdaq listing-compliance resolution. A reverse split or capital raise could keep the stock listed; continued sub-$1 trading with no compliance action confirms the drift.

On the calendar: 2026-11-10 — Q3 2026 earnings

Read the AI verdict on $KALA

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Ophthalmic biotech using mucus-penetrating nanoparticle (MPP) drug delivery to treat inflammatory eye diseases.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $KALA.

Biotechnology · Healthcare

mRNA oncology platform is the week's catalyst — Merck CEO hinted positive MRNA melanoma Phase 3 data (Oct readout, potentially doubling cancer-free rate vs Keytruda), driving MRNA +8%. IBB +41% T12M reflects the GLP-1, gene-editing, and RNA-medicine premium multiples re-rating the sector. ALT +14.2% since earnings confirms GLP-1 pipeline names as the most active near-term catalyst cohort.

What this means for $KALA

Neutral — ophthalmic nanoparticle delivery for inflammatory eye diseases sits outside mRNA, GLP-1, and gene-editing categories; company-specific pipeline execution is the sole driver.

Top industry ETF

$IBBiShares Biotechnology ETF
+19.3%YTD
+43.6%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-1.5How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-282%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-32.9%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-13.4%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 19, 2026$-21.32$-6.00-255.3%
Q1 2026May 15, 2026$-0.14$-8.50+98.4%
Q1 2026Apr 15, 2026$0.08$-16.00+100.5%
Q3 2025Nov 19, 2025$-1.07$-50.50+97.9%
Next earningsTue, Nov 10·consensus EPS $-6.00

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-0.20$-2.9M
Q4 FY25$0———$0.08$-4.6M
Q3 FY25$0———$-1.07$-10.9M
Q2 FY25$0———$-1.71$-7.7M

Forward consensus

4-year forecast · up to 1 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$25.0M$25.0M – $25.0M-$26.50-$26.50 – -$26.501
FY27$26.1M$26.1M – $26.1M-$20.00-$20.00 – -$20.001
FY28$134.2M$134.2M – $134.2M-$9.00-$9.00 – -$9.001
FY29$229.3M$229.3M – $229.3M-$8.50-$8.50 – -$8.501

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.3×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.0%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-32.3%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-95.8%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 18.6M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.9% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β-2.295-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KMaterial agreementSep 108-K — Item 1.01: Material agreement
AI summary

KALA BIO entered an exclusive distribution and reseller agreement with Virotek for ophthalmic genetic testing services in the United States, on a 50/50 profit-sharing basis. The partnership expands KALA's commercial reach into ophthalmic genetic diagnostics, complementing its ophthalmology drug pipeline. Equal profit sharing aligns both parties' incentives to grow the U.S. ophthalmic genetic testing revenue stream.

8-KOther eventSep 98-K — Item 5.08 · Item 8.01: Other event
AI summary

KALA Bio (KALA) set November 3, 2026 as the date for its next annual stockholder meeting and notified stockholders that proposal submissions must be received by September 19, 2026. The filing is a routine procedural notice required under SEC rules.

8-KListing / delisting noticeAug 288-K — Item 3.01: Listing / delisting notice
AI summary

Kala Bio received a Nasdaq Staff Deficiency Letter on August 27, 2026, notifying the company that its common stock has closed below the $1.00 minimum bid price for 30 consecutive business days (July 16 – August 26, 2026), triggering a listing deficiency under Nasdaq Listing Rule 5550(a)(2). Kala is ineligible for the standard 180-day compliance period because it completed a 1-for-50 reverse stock split in May 2026 to regain compliance — Nasdaq rules prohibit a second grace period within one year of using a reverse split to remedy the same deficiency. The company intends to appeal the delisting determination to a Nasdaq Hearings Panel. This is a material near-term risk for shareholders, as failure to win the appeal would result in KALA shares being delisted from Nasdaq.

424B5Prospectus supplement (offering)Jul 22424B5
AI summary

KALA filed a 424B5 prospectus supplement offering $250M at $0.001/share. This is a live, priced offering representing immediate dilution to existing shareholders. Proceeds are intended for stated in the supplement. Investors should assess the dilutive impact relative to current market cap and cash position.

SC 13D/AActivist amendmentJul 2SC 13D/A
AI summary

An amended SC 13D for KALA BIO discloses the reporting person converted Series AA Preferred Stock (purchased under a prior SPA) into 719,404 common shares at an aggregate cost of $1,308,007, based on 18,589,787 shares outstanding as of June 9, 2026. Post-conversion percentage is not stated in the excerpt. Update to a previously disclosed position following preferred-to-common conversion.

S-3/AShelf registrationJun 12S-3/A
AI summary

Kala Bio (KALA) filed Amendment No. 1 to its Form S-3 shelf registration (Registration No. 333-295667) on June 12, 2026 as a smaller reporting company. This is a routine amendment to an existing shelf filing, typically filed to update financial statements or other disclosure; no new offering terms were specified in the excerpt.

S-3Shelf registrationMay 7S-3
AI summary

Kala Bio (KALA) filed an initial Form S-3 shelf registration statement on May 7, 2026 as a smaller reporting company. The specific aggregate offering amount was not disclosed in the excerpt. This is a routine shelf filing enabling future capital raises.

8-KCharter amendmentMay 78-K — Item 3.03 · Item 5.03: Charter amendment · Item 8.01: Other event
AI summary

Kala Bio (KALA) effected a 1-for-50 reverse stock split, effective May 8, 2026 at 4:05 PM Delaware time. The Certificate of Amendment to the Certificate of Incorporation was filed on May 7, 2026 (Item 5.03). The split also triggered Item 3.03 (material modification to rights of holders) and Item 8.01. Reverse splits at this ratio typically reflect a stock trading at very low prices, potentially to regain or maintain exchange listing compliance.

+ 9 other (2 10-Qs · 1 PRE 14A · 1 NT 10-Q · 1 routine 8-K) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Kala Bio and Virotek Finalize Definitive Agreement Establishing Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Programglobenewswire.com·14d agoKala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Programglobenewswire.com·16d agoKALA BIO (KALA) Expected to Post Earnings on Thursdaydefenseworld.net·49d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$ALT$MRNA$AURA$NWBO$IBRX$SLS$IOVA$CMPS
Voices on X · last 7 days

No standout posts about $KALA on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport